Prelude Therapeutics Incorporated
PRLD
Rank in Stocks
#16288
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company... Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Share Price
$3.76
Last synced: 2026-11-09
Market Cap
$217.63M
Change (1 day)
4.44%
Change (1 year)
178.52%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Prelude Therapeutics Incorporated (PRLD)
Category
Healthcare
Operating Margin for Prelude Therapeutics Incorporated (PRLD)
Operating Margin as of November 2026 TTM: -300.56%
According to Prelude Therapeutics Incorporated's latest financial reports, its current operating margin (TTM) is -300.56%. At the end of 2025 the company had an operating margin of -861.33%.
Operating Margin history for Prelude Therapeutics Incorporated from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -300.56% | -65.11% |
| 2025 | -861.33% | -56.85% |
| 2024 | -1,995.91% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.13% |
US
|
|
| -149.01% | -99.50% |
US
|
|
| 25.57% | -100.09% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.10% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Prelude Therapeutics Incorporated's operating margin
What is Prelude Therapeutics Incorporated's operating margin?
Prelude Therapeutics Incorporated's operating margin is -300.56%, as of Nov 2026.
What was Prelude Therapeutics Incorporated's operating margin in 2025?
In 2025, Prelude Therapeutics Incorporated's operating margin was -861.33%, compared with -1,995.91% in 2024.
How has Prelude Therapeutics Incorporated's operating margin changed since 2020?
From 2020 to 2025, Prelude Therapeutics Incorporated's operating margin was highest in 2023 (0.00%) and lowest in 2024 (-1,995.91%).
How does Prelude Therapeutics Incorporated's operating margin compare with similar companies?
Prelude Therapeutics Incorporated's operating margin (-300.56%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.